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The rapid improvements in DNA synthesis technology hold the potential to revolutionize biosciences in
the near future. Traditional genetic engineering methods are template dependent and make extensive but
laborious use of site-directed mutagenesis to explore the impact of small variations on an existing sequence
‘‘theme.’’ De novo gene and genome synthesis frees the investigator from the restrictions of the pre-existing
template and allows for the rational design of any conceivable new sequence theme.
Viruses, being among the simplest replicating entities, have been at the forefront of the advancing biosci-
ences since the dawn of molecular biology. Viral genomes, especially those of RNA viruses, are relatively
short, often less than 10,000 bases long, making them amenable to whole genome synthesis with the
currently available technology. For this reason viruses are once again poised to lead the way in the budding
field of synthetic biology—for better or worse.Chemistry & Biorecent synthesis of 582,970 bp corresponding to the first artificial
bacterial genome by the group of Craig Venter (Gibson et al.,
2008). Starting with 101 prefabricated segments of 5–7 kb in
length (purchased from commercial vendors), Gibson et al.
used state-of-the-art methods and brute force to assemble
larger and larger DNA pieces, at first by recombination in
bacteria, and finally in yeast (Gibson et al., 2008). Alas, the
synthetic genome was not, or could not, be ‘‘booted’’ to life,
by transplanting the genome into an ‘‘empty’’ chassis as the
group has shown previously with a natural genome (Lartigue
et al., 2007). Therefore, the first synthetic autonomous life form
is still just below the horizon.
Methods for the Assembly of Long Synthetic DNA
It is not yet possible to synthesize entire genes as long contin-
uous strands of DNA from scratch. Rather, all synthetic genes
are assembled from short custom-made single-stranded DNA
oligonucleotides or ‘‘oligos,’’ which are literally strings of a few
nucleotides. Oligos are by-and-large still synthesized the same
way as they were 15 or 20 years ago. Through incremental
improvements in instrumentation and higher throughput, oligos
have become a cheap commodity for use in standard recombi-
nant DNA technologies. But, more than anything else, great
demand and even greater competition by manufacturers have
driven the oligo prices down by about 10-fold over the past
15 years (Figure 2). In comparison, the prices of finished,
sequence-confirmed gene synthesis by commercial gene
foundries have plummeted 50-fold in only 10 years (Figure 2).
As a reference point, at the outset of the poliovirus synthesis
project (Cello et al., 2002) in 1999, commercial gene synthesis
was simply unheard of. As recently as 2000, after much search-
ing, we found a vendor who agreed to synthesize parts of the
genome by special arrangement at a price of $12/bp (Cello
et al., 2002).A Brief History of DNA Synthesis
The chemical synthesis of nucleotide chains took its first infant
steps soon after the discovery of the DNA double helix. The
race to elucidate the genetic code was driven by the use of triplet
sequences of ribonucleotides synthesized by liquid-phase
chemistry. Depending on their sequence these triplets selec-
tively interactedwith amino-acylated tRNA (the codon:anticodon
recognition) (Nirenberg and Leder, 1964; Soll et al., 1965), which
led to the assignment of codons to their respective amino acids,
and to a much-deserved Nobel Prize for these heroic efforts in
these earliest days of synthetic biology. Khorana’s group
‘‘raced’’ to synthesize the first DNA copy of the 75 base pair
(bp) tRNAAla in 1970 (Agarwal et al., 1970), a monumental task
requiring 20man-years of labor, only to be outclassed by himself
in 1979 by a 207 bp DNA cassette containing the tyrosine
suppressor tRNA gene (Khorana, 1979).
The innovations of synthesizing DNA oligonucleotides (‘‘oli-
gos’’) on solid supports (Letsinger and Mahadevan, 1965)
combined with new activated phosphoramidite nucleosides
(Caruthers et al., 1987) led to steady improvements in the avail-
ability of quality oligos up to 100 bases long. This resulted in
a boost in gene synthesis activity throughout the 1990s that
continues unabatedly today. Some of themost notable synthesis
achievements are summarized in Figure 1 (Agarwal et al., 1970;
Becker et al., 2008; Blight et al., 2000; Cello et al., 2002; Chan
et al., 2005; Edge et al., 1981; Ferretti et al., 1986; Gibson
et al., 2008; Gupta et al., 1968; Kalman et al., 1990; Khorana,
1979; Kodumal et al., 2004; Nirenberg and Leder, 1964; Pan
et al., 1999; Soll et al., 1965; Stemmer et al., 1995; Tian et al.,
2004). Significant landmarks include the synthesis of an entire
2.7 kb plasmid sequence by Stemmer et al. (1995), the 4.9 kb
MSP-1 gene of Plasmodium (Pan et al., 1999), the 7.5 kb of the
poliovirus genome as the first synthetic self replicating organism
(Cello et al., 2002), and the 32 kb polyketide synthase gene
cluster (Kodumal et al., 2004). The trend has culminated in thelogy 16, March 27, 2009 ª2009 Elsevier Ltd All rights reserved 337
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ReviewFigure 1. Pushing the Limits: a Historical Progression of Notable Achievements in Gene Synthesis with References
Each point represents a report of an individual gene synthesis accomplishment with respect to the length of the synthetic sequence and the year it was first
reported.338 Chemistry & Biology 16, March 27, 2009 ª2009 Elsevier Ltd Allmethod is high yielding but costly ($0.10–0.20 per nucleotide
synthesis cost), which is a critical aspect if the oligos are needed
for the assembly of long DNA sequences. The price given above
translates into an oligonucleotide cost of approximately $200–
400 fora 1kbDNAsequence—and that’s for the rawmaterial only.
The development of optical deprotection chemistries heralded
a new era of parallel synthesismethods onmicro biochips (FodorIn the ideal world, an efficient and economical de novo gene
synthesis platform would combine cheap error-free oligo
synthesis with accurate assembly methods. Neither one is
currently available. There are two dramatically different methods
of synthesizing oligos. In the traditional, time-proven method of
solid-phaseoligo synthesis, eacholigo is synthesized individually,
on a separate small column or a well on a multiwell plate. TheFigure 2. Price Development of
Oligonucleotide Synthesis and De Novo
Gene Synthesis
Shown are the approximate end user prices per
base for oligonucleotides (desalted, nonpurified)
or per base pair for synthetic genes (below 3 kb,
sequence guaranteed). The data were compiled
from a ‘‘look back’’ of vendor invoices, and
a survey among colleagues. Although by no
means comprehensive, the prices shown here
are representative of what the typical research
laboratory paid for these services at the time.rights reserved
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Depending on the chip platform being used, several thousands
to hundreds of thousands of distinct oligonucleotides can
theoretically be synthesized on a single chip.
In an ingenious extension Tian and colleagues (Tian et al.,
2004) mated the light-induced deprotection chemistry with
microfluidic technology that allows the programmable synthesis
of thousands individual oligonucleotides on a tiny chip (Fig-
ure 3A). At the heart of this method is the digital light processing
technology that was developed for digital projectors and high-
definition projection television sets. On a microfluidic chip
containing a labyrinth of thousands of connected tiny reaction
chambers (Figure 3C), each chamber is computer-addressable
by a light beam generated on a digital micromirror device
(Singh-Gasson et al., 1999) (akin to the individual color light
spots making up the projection-television picture). A DNA
synthesis mixture containing the first nucleotide (A, for instance)
is pumped through the system. Here, A only ‘‘sticks’’ to the
chambers that call for an A at the specific position in their
sequence, which are the ones that are being illuminated at that
time (Figure 3A). Although all chambers receive the same
synthesis mixture at any given time, no reaction occurs in the
chambers that are ‘‘left in the dark’’ (in the example above, the
ones that need a C, G, or T at their corresponding position). After
the first reaction, the A-mix is washed out and the next reaction
mix containing the next nucleotide is pumped in and the process
is repeated, four times in total. After all four nucleotide reaction
mixes have gone through the chip, in each chamber the oligonu-
Figure 3. Microfluidic Chip Technology
Coupled with Light-Activated Chemistries
Hold Great Promise for the Massive Parallel
Synthesis of Oligonucleotides
(A, B) On an array of tiny flippable mirrors, each
mirror can be separately computer controlled
(flipped to an ‘‘ON’’ or ‘‘OFF’’ position). Mirrors in
the ON position reflect light onto their correspond-
ing reaction chamber on a microfluidic chip (bright
blue spots), leading to the incorporation of the
nucleotide currently loaded on the chip (here,
A-mix). Although all chambers receive the same
nucleotide mix at any one time, no reaction occurs
in the dark chambers (black spots). The process is
repeated with the next nucleotide mix and a new
light pattern, which specifies the chambers to
incorporate the new nucleotide. After the last
nucleotides are incorporated, the finished oligos
are released from the chip and collected as
a pool (B) actual size of a microfluidic chip holding
4000 sequence features. Reproduced with
permission by LC Sciences, LLC, Houston, Texas.
(C) A magnified view of the interconnected
microscopic reaction chambers on an Atactic
microfluidic chip. Reproduced with permission
by LC Sciences, LLC, Houston, Texas.
cleotide chain has now grown by at least
one nucleotide of the desired sequence.
At the end of the reaction, the oligonu-
cleotides are eluted from the chambers
as a single pool. Each of the oligo
sequences is only present in minute
quantities. This might present a challenge
in further increasing the throughput by increasing the number of
reaction chambers per chip, while decreasing their size. Tian
et al. (2004) demonstrated the potential power of this technology
for the synthesis of large numbers of oligonucleotides to be used
in synthetic gene assembly.
Companies already offer parallel on-chip-synthesized custom
oligo mixtures that are amenable for gene synthesis (LC
Sciences, Houston, TX). Currently the price of a pool of 3912
90-mers is approximately $1000. This technology is still very
much in the exploratory stage. One inherent difficulty of the
method is that all oligos are released from the chip as a mixture.
The low yields of oligos that come off the chip (107–108 mole-
cules per sequence) are insufficient to drive a gene assembly
reaction, which mandates a postsynthesis polymerase chain
reaction (PCR) amplification step before oligos can be used.
For this purpose each oligo is synthesized with two flanking
generic adaptor sequences, which allows amplification of all
oligos in parallel in a single PCR reaction using the correspond-
ing adaptor primer pair (Figure 4) (Tian et al., 2004). Using distinct
sets of adaptors on distinct subsets of oligos in the same chip-
synthesis reaction allows the subsequent selective amplification
of a desired subset of oligos, for instance a set necessary for the
assembly of one particular gene. Therefore, it is possible that in
a separate reaction a different set of oligos can be amplified from
the same chip-eluted oligo mix. Thus, fractioning the entire oligo
pool into gene-specific subsets will reduce complexity of the
mixture, increase concentration of each specific oligo, and
reduce potential interference or cross-hybridization from otherChemistry & Biology 16, March 27, 2009 ª2009 Elsevier Ltd All rights reserved 339
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individual sequences synthesized on the chip increases. The
higher the number of discrete oligo sequences synthesized per
chip, the lower the absolute yield per oligonucleotide (subfemto-
molar range) because the total yield of DNA is a direct function of
the total reaction surface on the chip. With more distinct oligos
the potential for unwanted cross-hybridizations during the
gene assembly step also increases.
The second drawback of the chip-based oligo synthesis is
that the PCR amplified oligos are now in a double stranded form.
The presence of a perfectly matched antisense strand might
reduce the efficiency in the subsequent assembly of these
oligos into larger genes. The assembly reaction depends on
the complementarity of the overlapping ‘‘construction’’ oligos,
those designed to build the gene, and the antisense oligos are
Figure 4. Assembly of Gene Sequences from Chip-Synthesized
Oligonucleotides
The pool of overlapping oligos in minute amounts is released from the
microchip, followed by PCR amplification with universal adaptor primers.
Double-strand copies produced in this way are subjected to type II restriction
enzymes to remove the adaptor sequence. Construction oligos are purified by
stringent hybridization to immobilized selection oligos. This leads to the
elimination of the unwanted antisense oligos and reduces the error frequency
in the construction oligos. Next, the eluted construction oligos are heat dena-
tured and reannealed, and subjected to PCR cycling to produce intermediate
or final DNA products. The reaction is driven by excess concentration of
a gene-flanking primer pair.340 Chemistry & Biology 16, March 27, 2009 ª2009 Elsevier Ltd Alllikely to compete more effectively for the same hybridization
partner. To overcome this problem the desired single stranded
construction oligos can be selectively enriched by specific
hybridization to antisense selection-oligos affixed to a column
and subsequent elution (Tian et al., 2004). When done under
stringent enough conditions, this procedure also contributes to
a significant elimination of error-containing oligos, because
they produce mismatches with the selection oligo and conse-
quently elute from the column at a lower temperature. On the
downside, this method requires twice the amount of selection
oligos than there are construction oligos. In other words, to
produce one chip’s worth of oligos, one needs two additional
chips worth of selection oligos, tripling the cost of synthesis
(Tian et al., 2004). This brings the current ‘‘rock-bottom’’ cost
of the final construction oligos before the gene assembly to
about $0.03/bp.
Although these new multiplex synthesis systems are techni-
cally feasible, it is our understanding that the major suppliers
of large synthetic DNA for now continue to assemble genes
from individually synthesized overlapping oligonucleotides by
traditional methods.
The sheer number of different oligonucleotides synthesized on
a chip mandates the use of new software programs to handle the
complexity of possible interactions of the various oligo
sequences in the mix (Czar et al., 2009). Several software
programs are freely available to design optimal sets of assembly
oligonucleotides. The basic tasks that successful software
needs to perform are:
1. Breaking down the target sequences to be synthesized
into suitable overlapping oligos.
2. Designing hybridization units, the overlapping portion
between two oligos, with the same melting temperature.
3. Ensuring hybridization specificity of each oligo pair to
eliminate potential cross-hybridization by choosing the
best possible breaking points between oligos for a partic-
ular gene, and by altering synonymous codons.
Assembly of Synthetic Genes and Genomes
There are two basic methods available for assembling long DNA
sequences, such as virus genomes, from short overlapping
synthetic oligonucleotides: direct assembly PCR, and ligase
chain reaction (LCR) followed by fusion PCR with flanking
primers.
Assembly PCR
Assembly PCR is based on the principle of generating stepwise
elongation of the amplicon, a piece of DNA formed in an amplifi-
cation event, by one oligonucleotide at each end of the growing
amplicon with each PCR cycle (Stemmer et al., 1995), and on the
possibility of intermediate products to act as overlapping mega-
primers to assemble even larger amplicons (Figure 4). Theoreti-
cally, the reaction continues until the two outermost oligos are
incorporated to give the full-length product. The full-length
product is subsequently amplified with an excess of the two
flanking PCR primers. Practically, obtaining large DNA frag-
ments in a single assembly reaction is exceedingly difficult. For
this reason, and for error-management purposes, it is generally
necessary to first synthesize, clone, and verify the sequence ofrights reserved
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can then be linked by fusion PCR to form larger genes or by
standard cloning methods.
LCR followed by Fusion PCR with Flanking Primers
The LCR method is similar in that it uses overlapping oligos. But
unlike with PCR assembly, oligos for LCR have to be designed
to anneal without gaps between them, head to toe, forming an-
nealed stretches of DNA that are then ligated using a thermo-
stable DNA ligase (Barany, 1991). In contrast to PCR assembly,
where a single oligo is added at each end of a synthon in each
cycle, during LCR several overlapping oligos can be ligated to
one another. Owing to the thermostability of the ligase, LCR
can be cycled similar to a PCR reaction, leading to assembly
of longer and longer chains, but no net amplification. The desired
product is finally amplified by PCR using gene-flanking primers.
Limitations of Current Oligo-Based DNA Synthesis
Methods
Regardless of the many variations on the theme of how to
assemble a large synthetic DNA, at the core of all current
methods are chemically synthesized oligonucleotides. The
downward price trend for oligos has slowed significantly over
the past 5 years and appears to be bottoming out (currently in
the $0.10–0.20/base range). Because the price gap, and there-
fore the profitmargin, between finished synthetic genes and their
oligo building blocks is narrowing, it can be expected that oligo-
based gene synthesis prices will soon follow. For long DNA
synthesis to become economical, radically new technologies
need to be developed that either reduce the errors in run-of-
the-mill oligos by orders of magnitude, or allow de novo gene
synthesis independent of the error-prone oligonucleotide chem-
istry, perhaps by developing enzyme-based synthesis of long
accurate polynucleotides. Barring such breakthrough, the
routine synthesis of bacterial or larger genomes will likely remain
prohibitively expensive for some time to come. As a case in
point, the recent synthesis of the Mycoplasma genome (Gibson
et al., 2008) cost an estimated $10 million (Herper, 2007). At
the research level, however, once gene synthesis hits the
$0.10–0.20/bp price range, synthesis will very likely replace the
traditional recombinant DNA methods for many smaller scale
cloning projects within the next few years.
A major problem with genes assembled from overlapping
oligos is the inherent error rate of about 1% during the chemical
synthesis of the oligos themselves. Themost frequent error is the
failure to incorporate bases due to less than perfect deprotection
of the reactive groups or incorporation of the incoming nucleo-
tide. It appears that there is a rather hard limit for improving
the oligo accuracy during the synthesis step much beyond the
1/100. Therefore, several techniques are being employed, often
in combination, to improve the accuracy of oligos and the
assembled DNA intermediates.
1. Keeping the oligos and the overlapping regions between
them short (40–50 bases) not only reduces the relative
error rate per nucleotide in the oligo, but also increases
the disruptive effect of mismatches between annealed oli-
gos. Using stringent hybridization conditions thus reduces
the chance of incorrect oligos to partake in the assembly
reaction (Young and Dong, 2004).Chemistry & Bio2. A common approach is to gel-purify oligos before the
assembly reaction, which helps eliminate many of the
shorter aberrant oligo species. This reduces the error
rate to about 1 in 500. At this error rate, short (several
hundred base pairs long), intermediate assembly products
are cloned by traditional recombinant DNA methods and
sequence verified. The vetted sequence segments are
then either combined by further rounds of cloning, or by
assembly PCR. The need for gel purification is another
reason to keep oligo length limited, because oligos that
are too long can no longer be effectively separated from
the most troublesome offender, the (N-1)-mer. If all
construction oligos for one specific synthesis project are
kept the same length, the gel purification can be done by
combining all oligos in one sample, much reducing time
and cost (Smith et al., 2003).
3. Another approach relies on the selective hybridization of
the construction oligos to a column of immobilized selec-
tion oligos (Tian et al., 2004), as noted above.
4. Finally, a second tier of error correction can be imple-
mented after the LCR or PCR assembly of gene fragments.
It is based on the enzymatic activity of T7 endonuclease,
which recognizes and specifically cleaves dsDNA at mis-
matched nucleotide pairs (Picksley et al., 1990; Young
and Dong, 2004). Following the final PCR amplification,
the DNA amplicon is heat denatured and reannealed.
Because mutations in the original construction oligo
sequences are distributed randomly, the probability of
two hybridizing strands carrying a mutation on one and
the corresponding compensatory mutation on the other
oligo is miniscule. It can therefore be expected that virtu-
ally every mutation in every oligo that participates in the
assembly reaction will create a mismatch. Similarly, error
correction by mismatch binding proteins, such as MutS
of Thermus aquaticus, can be employed, facilitating the
separation of the MutS-bound mismatched DNA from
the correct DNA by gel electrophoresis (Carr et al., 2004).
The quality of the oligos critically determines the practical size
of the synthesis intermediates that need to be cloned and
sequence verified (Carr et al., 2004). If sequence errors follow
a normal Gaussian distribution along the length of the DNA, an
error rate of 1 in 600 would make it impractical to assemble
a DNA longer than 1–2 kb in a single reaction without interme-
diate sequence verification (Figure 5).
Applications of De Novo Gene and Genome Synthesis
Codon Optimization
In many cases it is desirable to express a gene of interest (often
a human gene) in a heterologous, more economical expression
system, such as bacteria or yeast. All too often, however, the
codon usage within the gene is at odds with the codon usage
of the new host species. As a result the gene expresses poorly.
Thus, the need for ‘‘codon optimization’’ was born (Itakura et al.,
1977). During codon optimization, the codon usage of the gene is
altered to reflect that of the host species by replacing suboptimal
codons with preferred synonymous codons. Because this often
involves many simultaneous sequence changes, it is best done
by de novo gene synthesis. Probably the best known examplelogy 16, March 27, 2009 ª2009 Elsevier Ltd All rights reserved 341
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Error Rate on the Accuracy of Assembled
Synthetic Genes
The various curves assume error rates in the
construction oligonucleotides typically achieved
after different error-correction methods used to
assemble a target sequence are 1/600 (red; using
gel-purified oligos), 1/1,400 (blue; using hybridiza-
tion-selected oligos), and 1/10,000 (black; using
mismatch-specific endonucleases). Adapted
from Carr et al., 2004.342 Chemistry & Biology 16, March 27, 2009 ª2009 Elsevier Ltd Alldirect predecessors and competitors. This selection process
however does not follow what humans would consider a logical
design process. Evolutionary changes are small and incremental
following a one-directional ratchet that does not move back-
ward. There is no ‘‘reset’’ button that allows evolution to jump
back to an earlier version and try again. De novo gene and
genome synthesis provides this virtual reset button by allowing
the creation of any conceivable genome at will and at once, no
matter how different from its predecessor.
One recurring theme in viral genomes is the evolution of over-
lapping reading frames. This space-saving measure allows
a virus to encode portions of two proteins on the same stretch
of genome sequence, but in two different reading frames.
Studying individual genes and proteins of such a virus genetically
and biochemically poses a problem for the experimenter,
because manipulating one protein inadvertently changes the
other. To simplify these interdependencies in the genome,
Chan and colleagues redesigned and synthesized parts of the
bacteriophage T7 genome, eliminating the overlapping reading
frames (Chan et al., 2005). In the resulting virus, the individual
genes could be then manipulated and studied independently,
a process they called ‘‘refactoring’’ in analogy to the process
of redesigning and improving computer code, while retaining
its basic function.
Exploiting the Intrinsic Sequence Biases of the Human
Genome for the Generation of Synthetic Virus Vaccines
The basic mechanism of mRNA translation is preserved from the
simplest virus to the most complex organism. Viruses, just like
human cells, need to produce mRNA molecules, which are
used to convert their genetic information into proteins. Different
viruses have devised different strategies to accomplish this, and
have different ways to store this genetic information in their
genome. Invariably, however, viruses need to divert the host’s
cellular machinery for the translation of their proteins, because
they themselves cannot execute this function. The degeneracy
in the genetic code (several synonymous codons specify the
same amino acid) gives an organism the flexibility to encode
a given protein sequence in its genome in an unimaginably large
number of ways. The poliovirus polyprotein, for instance, could
be encoded by a staggering 101100 different mRNA sequences,
all of them specifying the same protein sequence (for compar-
ison, the number of atoms in the observable universe is
estimated to be on the order of 1080). This raises the question:
To what extent is the natural encoding of a gene optimal orof codon optimization is the ‘‘humanization’’ of the green fluores-
cent protein of the jellyfish A. victoria (Zolotukhin et al., 1996).
Codon optimization is currently still the most prevalent reason
for de novo gene synthesis (Gustafsson et al., 2004).
In some instances gene synthesis has been used to recreate
a DNA sequence from a publicly available sequence database
in an effort to sidestep licensing, patenting, or material transfer
issues.
Creating New Chassis for Protein Engineering
It is theoretically possible to synthesize a bacterial genome in
which the redundancy of the genetic code is eliminated, such
that each amino acid in every bacterial protein is represented
by exactly one codon only. Thus, only 20 codons plus 1 stop
codon would be needed to synthesize all the bacteria’s own
genes. At the same time, the remaining 43 ‘‘orphaned’’ codons
could be freed up to specify non-natural amino acids. Bacteria
with such an expanded genetic code could one day become
a powerful chassis for the production of artificial proteins (Carr
and Isaacs, 2006; The Economist, 2006).
Viral Gene and Genome Synthesis
Viruses are among the simplest replicating genetic systems. For
this reason they have been at the forefront of the advancing
biosciences since the dawn of molecular biology. Their small
genome sizes (most RNA virus genomes are 10 ± 5 kb) makes
them amenable to whole genome synthesis with the currently
available technology. For this reason viruses are poised to lead
the way in the budding field of synthetic biology.
A significant use for genome synthesis consists in the recrea-
tion of viruses or perhaps other organisms in the future, for which
no intact natural template is available. The synthesis of the 1918
flu virus was accomplished by piecing together sequence frag-
ments recovered from victims buried in the Alaskan permafrost
and archived tissue samples (Tumpey et al., 2005). The creation
of bat SARS coronavirus (Becker et al., 2008) and HIV from
Chimpanzee feces (Takehisa et al., 2007) also falls into this cate-
gory. A clever extension of this idea has been the resurrection of
live infectious retroviruses assembled from a consensus of
ancient remnants that are endogenous to the human genome,
and which have perhaps been inactive for millions of years (Dew-
annieux et al., 2006; Lee and Bieniasz, 2007). Once the stuff of
science fiction movies, these ‘‘Jurassic Parkesque’’ projects
are likely to be just the teaser trailers of the coming attractions
in the budding synthetic technology.
Through the process of natural selection, evolution favors
systems that work, especially those that work better than theirrights reserved
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(A) Example of the level of sequence alteration after codon reassignment of the poliovirus capsid gene (Mueller et al., 2006). PV(M), part of the wild-type capsid
coding sequence; PV-AB, the same amino acid sequence encoded by rare codons; PV-SD, the same amino acid sequence encoded by random shuffling
of synonymous codons present in the wild-type sequence. Note that the amino acid sequence encoded by all three sequences remains the same.
(B) Codon pair bias after SAVE-mediated codon reassignment of viral genes. The codon pair bias (CPB) score for each of 14,795 confirmed annotated
human genes was calculated. Each red dot represents the calculated CPB score of one human gene plotted against its amino acid length. Predominant use
of underrepresented codon pairs yields negative CPB scores. The codon-pair scores of three wild-type viral genes fall within the bulk of the human genes. After
computer-aided recoding and de novo synthesis of the viral genome according to the SAVE algorithm the new genes (‘‘Min’’ for minimized CPB) have extremely
unfavorable CPB, unlike any gene the cellular translation machinery has ever encountered. Note that the amino acid sequence of all proteins remains unchanged
during this process. By analogy to other virus systems a decreasing CPB leads to reduced translatability of the mRNA and increased attenuation of the virus.
Adapted from Coleman et al., 2008.Chemistry & Bivantage against the host’s innate and immune defenses. One of
the major benefits of the whole-genome deoptimization strategy
is that the resulting attenuated viruses are phenotypically and
genotypically extremely stable. The attenuation (att) phenotype
is dependent onmany hundreds, even thousands, of silent muta-
tions, each by themselves virtually inconsequential, or ‘‘death by
a thousand cuts.’’ Therefore, the fitness gain from reverting indi-
vidual mutations appears to be too small to drive genetic selec-
tion, and thus, reversion apparently does not occur (Coleman
et al., 2008). We termed this process of perturbing intrinsic viral
genome biases by synthetic genome redesign SAVE (synthetic
attenuated virus engineering) (Figure 6).
SAVE attacks a virus at one of the most fundamental pro-
cesses common to all living systems, the translation of protein,
for which viruses depend on the host cell’s machinery. Thus, it
should be predicted that SAVE will work on most (if not any)
viruses.
The rational genetic changes imposed on SAVE-designed viral
genomes are completely independent of protein sequence. The
viral protein sequences, and therefore their function, remain
100% preserved in the recoding process. Therefore, an under-
standing of the proteins function is not necessary, sidestepping
the need of most of classic virology in order to produce an atten-
uated vaccine candidate in a very short time with a predictable
degree of attenuation in virtually any virus system. Virusesspecial? The cell’s preference of one synonymous codon over
another to specify the same amino acid is termed ‘‘codon
bias.’’ It is thought that codon bias is correlated with the abun-
dance of the corresponding cognate tRNAs in the cell. Conse-
quently, rare codons are associated with a suboptimal transla-
tion of an mRNA. In addition, the frequencies of which two
codons occur next to one another in the genome are not what
is statistically expected from the frequencies of the two codons
that make up the pair—a phenomenon called the ‘‘codon-pair
bias.’’ There are codon-pair combinations that are statistically
greatly underrepresented whereas others are greatly overrepre-
sented. The significance of codon pair bias has been largely
unknown and underappreciated. We have recently shown that
it is possible to exploit the codon-pair bias phenomenon for
the synthesis of novel live attenuated forms of viruses with
incredible properties (Coleman et al., 2008). By using large-scale
computer-aided redesign of the viral genome, we engineered
hundreds of silent mutations into poliovirus. These mutations
were targeted to introduce a maximum number of unfavorable
synonymous codon-pairs, without changing codon bias or
protein sequence. By forcing a virus to ‘‘make do’’ with this
heavily biased synthetic genome, we showed that viral protein
translation is greatly reduced. Thus, codon-pair deoptimized
viruses cannot reproduce their genetic information as quickly
as their wild-type cousins, which puts them at a decisive disad-ology 16, March 27, 2009 ª2009 Elsevier Ltd All rights reserved 343
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unnecessary genes around. By that rationale, most viral genes
product can be considered essential. Depending upon the virus
system, interfering just a little bit with the synthesis of several of
those genes turns out to pack a great punch against the overall
fitness of the virus (Coleman et al., 2008; Mueller et al., 2006).
Using the SAVE method we can profit from these genomic
biases that have arisen over evolutionary time-scales and turn
themupside down and inside out, undoing eons of viral evolution.
Ifwe thinkof evolutionas ‘‘walking’’ alongadirt path, SAVEallows
us to ‘‘leap’’ across the evolutionary universe at warp speed.
Because it is evident that many viruses have actively selected
against the occurrence of certain sequence features, such as
unfavorable codons, codon-pairs, and other sequences motifs,
the whole-genome recoding approach by de novo synthesis
will very likely have a profound effect on any virus.
General Requirements for the Application of SAVE
to a Virus System
Because SAVE targets a virus at the level of protein translation,
a function elementary to all viruses, we believe this approach is
applicable to many virus systems for which the following basic
requirements are met:
1. A target virus has a known genome sequence, preferably
available online.
2. The desired deoptimized genome sequence is prepared
by computer-aided redesign using the SAVE algorithm.
3. De novo synthesis of the artificial viral genome is per-
formed according to the design specifications, usually
outsourced to a commercial vendor.
4. A reverse genetics system is employed to boot the artificial
genome to life and make a virus. This is decidedly simple
for many human viruses. Often a genome-length copy of
the DNA itself or an RNA transcript of that DNA is infec-
tious upon transfection into susceptible cells.
5. A method to screen for viruses of desired phenotype has
to be available. An initial screen in susceptible cell culture
will yield valuable information as to the viability of various
deoptimized virus designs. Clearly the virus still must be
able to replicate at least at a low level in order to be useful
as a live vaccine.
6. A suitable animal model to test attenuation and immune
response is required.
If the above requirements are met, the SAVE strategy can
successfully be employed for redesign and synthesis of viruses.
Synthetic virology, i.e., the redesign and synthesis of custom-
tailored whole virus genomes, has become economically
feasible with recent rapid improvements in DNA synthesis tech-
nology. This holds the potential to revolutionize the way virology
and vaccinology is done. Viral genomes, especially of RNA
viruses and retroviruses, are short enough to make them
amenable to whole-genome synthesis with currently available
technology. Such freedom of design could provide tremendous
power to perform large-scale redesign of DNA/RNA coding
sequences, to study the impact of large-scale changes in codon
bias, codon-pair bias, dinucleotide biases, GC content, RNA
secondary structures, and other sequence signatures, on viral344 Chemistry & Biology 16, March 27, 2009 ª2009 Elsevier Ltd All rfitness, with the aim to develop a new platform for vaccine
design and genetic engineering.
Societal Implications of Synthetic Biology
What is synthetic biology? It is neither a field in its own right, nor
a separate science. It is perhaps best described as an improve-
ment of existing enabling technologies that are beginning to
penetrate mainstream sciences, as they become more and
more economical. This has led to an ‘‘organized’’ crossover of
different scientific fields (e.g., biology, chemistry, mathematics,
engineering) that promises to yield organisms with useful
biochemical pathways never seen before.
The new reality of synthetic genes and genomes calls for
a fundamental revision of the ways biology is taught to students.
The Johns Hopkins University has already embraced these
cutting-edge developments, and is now offering an undergrad-
uate course in which students collaboratively work toward
synthesizing the yeast genome. Impressively, within only 1 year
this unified effort resulted in the synthesis of hundreds of
750 bp cassettes amounting to the 280 kb of the yeast chromo-
some III (Dymond et al., 2009). An equally imaginative and playful
introduction to engineering of biological systems is fostered by
the International Genetically Engineered Machine Competition
(iGEM; http://www.igem.org) organized by synthetic biologists
at MIT. Here undergraduate teams compete in designing and
building genetic circuits and systems from an ever expanding
toolkit of standard genetic parts, or ‘‘BioBricks’’ (Goodman,
2008).
However, although the excitement about synthetic biology is
substantial enough, it faces equally big skepticism and ‘‘fear of
the new’’ in our society. A disservice to their own science is
perhaps the tendency of some researchers in the ‘‘synthetic
biology field’’ to overvalue its novelty and uniqueness. The
most commonly cited public concerns with regard to synthetic
biology are probably the ethical implications connected with
the creation of ‘‘new life forms’’ and the fear of synthetic ‘‘killer
viruses.’’ These sentiments are often picked up and fuelled by
the media, potentiating the perceived fear of the uncertain.
Virtually every organism ever modified in molecular or genetic
research is by definition a new life form. This definition could be
expanded to all naturally occurring organisms that genetically
differ from their parent—in other words: all the living creatures.
Why would an organism created by synthetic methods be qual-
itatively different? The question presents itself: Why do we, as a
society, worry more about the possibility of a synthetic designer
pathogen, when some of theworst pathogens known tomankind
are still raging? Measles virus, as a case in point, is one of the
most contagious viruses to humans. As recently as in 2000,
approximately 777,000 people died per year from measles,
and in third-world countries with poor health care systems the
fatality rate can be as high as 28% (Perry and Halsey, 2004).
Annually, 250,000–500,000 people die from complications of
the flu (WHO, 2003). Additionally, only a few critical mutations
in the H5N1 bird flu virus separate us from a virus that can easily
spread among humans and lead to an influenza pandemic. The
AIDS pandemic, caused by primate viruses that jumped the
species barrier to humans, claims approximately 2 million lives
annually (http://www.avert.org/worldstats.htm). In 2003, the
world barely escaped a pandemic by a SARS-coronavirus nowights reserved
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and references therein).
Although in theory at least, we have the capacity to generate
any genetic sequence that we can conceive, what we can do
with this capacity is in fact quite limited. Although it’s easy to
think up fantastic and scary scenarios of synthetic killer viruses
wiping out humankind, bioterrorists and the brightest scientific
thinkers alike would be hard pressed to saywhat such a designer
superpathogen would look like. In reality, all that can be accom-
plished via synthesis, now and for some time to come, is
emulating, copying, and re-creating what mother nature has
brought forth and thrown at us incessantly throughout our history
on this planet. It is possible to produce variations on an existing
theme. It is not possible, as yet, to design from scratch a qualita-
tively new pathogen that is completely different from any
organism that exists now or has existed in the past. The level
of abstraction required to ‘‘piece together’’ qualitatively new
life forms from defined off-the-shelf parts (genes) is far from
being realized (Goler et al., 2008). It is probably this misconcep-
tion, trumpeted by the media, which strikes a cord of fear in the
general population. Cases in point:
1. The 2002 poliovirus synthesis (Cello et al., 2002), the first
synthesis of a pathogen, caught the world off guard and
ignited a heated debate in its aftermath. All we had done
was to re-create an exact synthetic copy of the poliovirus
genome, except for some genetic ‘‘watermarks’’ to prove
the authenticity of the synthetic genome. The resulting
virus was, at the protein level, 100% identical to the
wild-type virus used in countless laboratories around the
world, a virus that even now naturally circulates in several
countries and that is available for purchase at repositories
such as the American Type Culture Collection. Being an
exact antigenic match to the currently available poliovirus
vaccine, an overwhelming proportion of the world popula-
tion is immune against this virus. Worldwide vaccine
coverage against poliovirus is arguably the greatest of
any vaccine-preventable disease. This is hardly a blueprint
for an imminent bioterrorist attack. But it was suddenly
becoming clear that viruses can never be regarded as
extinct, as long as their genome sequence information is
preserved, be it on a government-sponsored online data-
base, a 29-year-old Nature journal (Kitamura et al., 1980)
gathering dust in libraries across the world, or just written
down on a smudgy piece of paper forgotten in a desk
drawer. It is sufficient to re-create a virus at any point,
even long after any traces of its natural presence have van-
ished. It is this uncomfortable realization that brought
about the level of public discussion that the original polio-
virus synthesis had. The publication was intended not only
to herald a new era in the study of organisms, but also to
serve as a ‘‘wake-up call’’ for dual use technology.
2. The re-creation of the highly pathogenic 1918 flu virus
(Tumpey et al., 2005) out of sequences extracted from
influenza victims preserved in the northern permafrost
also met with criticism, although no one had maligned
the publication of the genome sequence as much as
8 years earlier (Taubenberger et al., 1997). In fact, the
synthesis the 1918 virus brought critical new insight intoChemistry & Biothe pathogenesis of the influenza and it is a prerequisite
for the production of an adequate vaccine should such
a need ever arise. Isn’t society in the long run much better
off with this knowledge than without it, understanding
1918 flu virus in detail rather than hoping that something
like the 1918 flu will never happen again? This sentiment
is even more inappropriate with the looming threat of the
H5N1 bird flu pandemic.
3. Over 30 years of random, ‘‘unenlightened’’ genetic manip-
ulation of viral genomes through recombinant DNA tech-
nology by countless laboratories around the world has
not shown any evidence that researchers would acciden-
tally and unbeknownst to them create a human supervirus.
Whole-genome synthesis will be no different.
4. The adaptation of a human pathogen to an experimental
animal species by repeated passaging through that
species (a decidedly ‘‘pre-synthetic era’’ method) has
been employed ever since viruses were discovered. It
leads to the increased pathogenicity in the new species
compared with the wild-type virus. These host-adapted
models have greatly facilitated the study of viruses and
the diseases they cause. Equally important is that these
experiments resulted in the development of some of the
most successful vaccines ever produced (polio, measles,
mumps, rubella, and smallpox). As it turned out, passaging
these viruses through diverse animal species lead to
the mitigation of their disease-causing potential for hu-
mans—a process termed ‘‘attenuation.’’
All the above considerations notwithstanding, de novo
genome synthesis, like many technologies in the past, does
hold a potential for dual use. And unlike many technologies
before it that require immense resources that cannot escape
detection (nuclear proliferation, for instance), the intentional
misuse of genome synthesis technologies will become increas-
ingly undetectable. It seems next to impossible that genome
synthesis can ever be government-regulated effectively. The
technology and its components are too ubiquitous already,
and too easy to jury-rig from off-the-shelf parts. The nature of
genome synthesis is such that in the very near future pathogens
can, and perhaps will, be synthesized in the proverbial hobby-
ist’s basement, high school science lab, or by a bioterrorist
organization. These possibilities are not an academic’s hyper-
bole either. In fact, the grassroots ‘‘biohacker’’ culture is already
flourishing outside the realm of academia, industry, and govern-
ment oversight (Cowell and Bobe, 2009). When considering
these issues, our society would be prudent to shift focus from
prevention of such dual-use proliferation to preparing for it.
The latter might include the development of new vaccines and/
or the stockpiling of available vaccines against the most likely
bioterrorist agents.
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